Differential maintenance of primitive human SCID-repopulating cells, clonogenic progenitors, and long-term culture-initiating cells after incubation on human bone marrow stromal cells

被引:127
作者
Gan, OI
Murdoch, B
Larochelle, A
Dick, JE
机构
[1] HOSP SICK CHILDREN,RES INST,DEPT GENET,TORONTO,ON M5G 1X8,CANADA
[2] UNIV TORONTO,DEPT MOL & MED GENET,TORONTO,ON,CANADA
关键词
D O I
10.1182/blood.V90.2.641.641_641_650
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Many experimental and clinical protocols are being developed that involve ex vivo culture of human hematopoietic cells on stroma or in the presence of cytokines. However, the effect of these manipulations on primitive hematopoietic cells is not known. Our severe combined immune-deficient mouse (SCID)-repopulating cell (SRC) assay detects primitive human hematopoietic cells based on their ability to repopulate the bone marrow (BM) of immune-deficient nonobese diabetic/SCID (NOD/SCID) mice. We have examined here the maintenance of SRC, colony-forming cells (CFC), and long-term culture-initiating cells (LTC-IC) during coculture of adult human BM or umbilical cord blood (CBI cells with allogeneic human stroma. Transplantation of cultured cells in equivalent doses as fresh cells resulted in lower levels of human cell engraftment after 1 and 2 weeks of culture for BM and CB, respectively. Similar results were obtained using CD34(+)-enriched CB cells. By limiting dilution analysis, the frequency of SRC in BM declined sixfold after 1 week of culture. In contrast to the toss of SRC as measured by reduced repopulating capacity, the transplanted inocula of cultured cells frequently contained equal or higher numbers of CFC and LTC-IC compared with the inocula of fresh cells. The differential maintenance of CFC/LTC-IC and SRC suggests that SRC are biologically distinct from the majority of these in vitro progenitors. This report demonstrates the importance of the SRC assay in the development of ex vivo conditions that will allow maintenance of primitive human hematopoietic cells with repopulating capacity. (C) 1997 by The American Society of Hematology.
引用
收藏
页码:641 / 650
页数:10
相关论文
共 38 条
[1]  
BARNETT MJ, 1994, BLOOD, V84, P724
[2]  
BARNETT MJ, 1989, BONE MARROW TRANSPL, V4, P345
[3]  
BHATIA M, IN PRESS P NATL ACAD
[4]   GENE-THERAPY IN PERIPHERAL-BLOOD LYMPHOCYTES AND BONE-MARROW FOR ADA(-) IMMUNODEFICIENT PATIENTS [J].
BORDIGNON, C ;
NOTARANGELO, LD ;
NOBILI, N ;
FERRARI, G ;
CASORATI, G ;
PANINA, P ;
MAZZOLARI, E ;
MAGGIONI, D ;
ROSSI, C ;
SERVIDA, P ;
UGAZIO, AG ;
MAVILIO, F .
SCIENCE, 1995, 270 (5235) :470-475
[5]  
BREEMS DA, 1994, LEUKEMIA, V8, P1095
[6]  
CASHMAN JD, IN PRESS BLOOD
[7]  
CHANG J, 1989, BONE MARROW TRANSPL, V4, P5
[8]  
COULOMBEL L, 1983, BLOOD, V62, P291
[9]  
Dick J E, 1996, Semin Immunol, V8, P197, DOI 10.1006/smim.1996.0025
[10]   PROLIFERATION OF TOTIPOTENT HEMATOPOIETIC STEM-CELLS INVITRO WITH RETENTION OF LONG-TERM COMPETITIVE INVIVO RECONSTITUTING ABILITY [J].
FRASER, CC ;
SZILVASSY, SJ ;
EAVES, CJ ;
HUMPHRIES, RK .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (05) :1968-1972